Read the DRAFT Clinical Policy (PDF)
The draft clinical policy related to reperfusion therapy for STEMI patients is in the review stage of ACEP clinical policy development. Comments on the draft are being sought by the ACEP Clinical Policies Committee. Please focus your comments on the clinical content of the document, and not copyediting. Document your comments in the format requested, making note of additional evidence as appropriate. All comments will be carefully reviewed by the Committee and used to further refine and enhance the draft when evidence supports the changes. Individual reviewer names will not be used in the final document. Comments do not imply endorsement of the document and will be stated as such in the final document. Please provide comments by April 13, 2017
For questions, please contact Rhonda Whitson, RHIA, at firstname.lastname@example.org. Thank you for providing comments.
Do you have any relevant industry relationships - Relationships with companies associated with products or services that significantly impact the specific aspect of disease addressed in the clinical policy draft on reperfusion therapy for STEMI that could pose a real or potential conflict of interest with respect to this guideline?
Area of Content/Concept
Justification (include reference if possible)